JB Ruddle, CA Harper, D Hönemann, JF … - British Journal of Ophthalmology, 2006 - bjo.bmj.com A 58 year old man with chronic lymphocytic leukaemia was enroalled in a clinical
trial of denileukin diftitox (Ontak, Ligand Pharmaceuticals) receiving 10
standard cycles of therapy with good response. 1 Eight months later his ... Cited by 8 - Related articles - All 6 versions
M Park, GT Liu, J Piltz-Seymour, CL Wisda, … - Leukemia & lymphoma, 2007 - informahealthcare.com Denileukin diftitox (DD; Ontak, Eisai, Woodcliff Lake, NJ) is an FDA-approved
targeted therapy for cutaneous T-cell lymphoma (CTCL) [1]. This recombinant
fusion protein (human interleukin 2 {IL-2} and diphtheria toxin) binds ... Cited by 7 - Related articles - BL Direct - All 6 versions
JB Ruddle, HM Prince - Leukemia & lymphoma, 2007 - Informa Pharma Science Denileukin diftitox (DD) is a novel immunotoxin approved in the USA for the
treatment of relapsed CD25 positive cutaneous T-cell lymphoma (CTCL). Its use in
other lymphoid malignancies and immunological conditions is being ... Cited by 3 - Related articles - BL Direct - All 6 versions
- ►iovs.org M Takeuchi, H Keino, T Kezuka, M Usui, O … - Investigative ophthalmology & visual science, 2004 - ARVO METHODS. Tr-depletion was achieved in (C57BL/6 x A/J) F1 (B6A) mice by
thymectomy on day 3 of life followed by intraperitoneal injection of an
anti-CD25 mAb. At 6 months of age, autoantibodies to the retina were ... Cited by 15 - Related articles - BL Direct - All 4 versions
M Lubow, DM Grzybowski, H Awad - Leukemia & Lymphoma, 2008 - informahealthcare.com DD is an important new immunomodulating agent, not only for its value in
cutaneous lymphoma, but for the insight it brings us about the role of
regulatory T-cells in autoimmune diseases. It is critical that we see the ... Related articles - BL Direct - All 4 versions
K Motaparthi, M Duvic - The Internet Journal of Dermatology, 2007 - ispub.com Denileukin diftitox (DAB389-IL-2, Ontak ® ) is an FDA-approved treatment for
patients with advanced or recurrent CTCL 1] . Denileukin diftitox (DD) is a
recombinant fusion protein consisting of diphtheria toxin fragment A (DTA) ... Related articles - Cached - All 2 versions
D Kaminetzky, KB Hymes, 2008 - pubmedcentral.nih.gov Cutaneous T-cell lymphoma/mycosis fungoides (CTCL/MF) is a rare
lymphoproliferative disorder which can present as an indolent or as an
aggressive process involving skin, lymph nodes, and blood. In stages IA, IB ... Related articles - All 5 versions
HM O'Leary, KJ Savage - Current Oncology Reports, 2008 - Springer Peripheral T-cell lymphomas (PTCLs) are a rare and het- erogeneous group of
disorders associated with a very poor prognosis. Historically, treatment
protocols have been largely based on regimens used to treat aggres- sive ... Related articles - All 3 versions
AL Harrison, M Duvic - The Internet Journal of Dermatology, 2004 - ispub.com Sčzary syndrome (SS) is the leukemic variant of Mycosis fungoides, the most
common form of cutaneous T-cell lymphoma (CTCL). The classic triad of
exfoliative erythroderma, lymphadenopathy, and pruritis plus increased ... Cited by 1 - Related articles - Cached - All 2 versions
JM Baumgartner, MD McCarter - Surgery, 2009 - Elsevier The power of the immune system represents a tantalizing mechanism for potential
tumor eradication in patients with cancer. Unfortunately, most immunologic
strategies designed to treat malignancy ultimately fail. Regulatory T cells ... Cited by 1 - Related articles - All 17 versions
